Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from KVUE

How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?

While recent performance trails the industry, Kenvue continues to retain measured analyst confidence and long-term relevance.

Barchart

Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

Barchart

Kenvue Stock: Analyst Estimates & Ratings

As Kenvue has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Preview: What to Expect From Kenvue’s Report

Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

Barchart

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

MarketBeat

Kenvue Stock: Is KVUE Underperforming the Consumer Defensive Sector?

As Kenvue has performed weaker than the consumer defensive sector over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue

Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred renewed interest in the sector, setting up a potential reshuffling of weightings across several big-name ETFs.

Benzinga

Amazon Surge Sends S&P 500, Nasdaq Higher to Start November: Stock Market Today

Amazon inked a $38 billion cloud deal with OpenAI, which sent the stock to the top of the Dow Jones on Monday.

Kiplinger

Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity

Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make sense due to the implied expansion of the acquiring entity's product portfolio. However, Kenvue has been ground zero for a controversy involving the flagship over-the-counter…

Benzinga

Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings

Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Barchart

Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here?

Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares heading into 2026.

Barchart

Kimberly-Clark Stock Plunges Over 16%, Kenvue Surges 20% In Monday Pre-Market: What's Going On?

Shares of Kimberly-Clark Corporation (NASDAQ:KMB) plunged 16.15% during the pre-market trading session on Monday, after it announced the acquisition of Kenvue Inc. (NYSE:KVUE) on Monday. Meanwhile Kenvue stock surged 20.04%.

Benzinga

Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations

Patience and a tolerance for risk may be necessary, but these Hold stocks could eventually see big gains, according to analysts.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading pregnant women about the safety of Tylenol despite evidence suggesting its active ingredient, acetaminophen, may increase the risk of autism and attention disorders in children.

Barchart

Unusually Active: 4 Options to Watch Next Month for Potential Future Gains

Overall options volume was about average on Thursday, with calls accounting for 60% of the action. Of the 1,291 unusually active options on the day, here are four to watch in the next month.

Barchart

Kenvue's Quarterly Earnings Preview: What You Need to Know

Kenvue is expected to announce its third-quarter results by early November, and analysts expect a notable decline in earnings.

Barchart

Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

This Billionaire Investor Is ‘Thrilled’ to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here?

Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy.

Benzinga

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Benzinga

Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again

Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With…

International Business Times UK

Smoke from Wildfires Chokes Austin: What Locals Are Breathing Tonight

Wildfire smoke blankets Austin, with haze from local and distant blazes prompting health alerts and raising questions about the city's fire readiness.

The Independent UK

Quadruple murder at Austin yogurt shop was one of city’s most infamous cold cases. 30 years later police have a suspect

Serial killer Robert Eugene Brashers, who died by suicide in 1999, committed at least seven murders across multiple states between 1990 and 1998, prior to the Austin yogurt shop killings

Barchart

As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?

Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.

Benzinga

Kenvue Surges Over 2% Pre-Market Despite Trump Administration's Autism Warning

Kenvue Inc. (NYSE:KVUE) saw its stock rise by 2.61% to $17.69 in pre-market trading on Wednesday, despite concerns stirred by President Trump's controversial comments about acetaminophen potentially being linked to autism.

1 2 3

People

Robert Eugene Brashers

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.